PharmaCorp Closes Previously Announced Western Canada Pharmacy Acquisition and Announces Two Additional Definitive Agreements
Purchase price of approximately $2.47 million Acquisition increases PharmaCorp's operating network to 16 pharmacies New definitive share purchase agreement executed for a PharmaChoice Canada-bannered pharmacy in Western Canada at a purchase price of approximately $1.3 million New definitive asset purchase agreement executed for the prescription files of an I.D.A.-bannered pharmacy in Western Canada Saskatoon, Saskatchew
Biotechnology, Pharmaceuticals, Retail
2026-08-18 8:00 AM EDT | PharmaCorp RX Inc.
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-18 7:00 AM EDT | TempraMed Technologies Ltd.
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval Program
2026-08-17 7:40 AM EDT | OS Therapies
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnology, Pharmaceuticals, Health
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Strategic Investment in Production Expansion: Impact Fusion International (IFUS) Installs Proprietary Machinery to Enhance Production Capacity
Napoleonville, Louisiana--(Newsfile Corp. - August 17, 2026) - IFUS (OTCID: IFUS) has installed a retrofitted Selco/Mosley Badger Double Ram Press. Per the Equipment Commissioning Plan, both SGP+™ and SAG™ will now be produced for validation to ensure consistent and sustainable product quality. Delivery and installation, supported by the Harris Bailer Distributor Crigler, has ensured that retrofitted production capability is consistent with IFUS' Proprietary Formulation and
2026-08-17 12:01 AM EDT | Impact Fusion International Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027
Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated. "While ATI-1801 remains the Company's principal
Biotechnology, Pharmaceuticals, industries.supplementary-medicine.name
2026-08-14 5:00 PM EDT | Appili Therapeutics Inc.
Secretary of State Randeep Sarai Visits University of Calgary to Learn About Biosenta's Tri-Filler(TM) Technology
Ontario and Calgary, Alberta--(Newsfile Corp. - August 14, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta") was honoured to welcome the Honourable Randeep Sarai, Secretary of State (International Development), to the University of Calgary for a visit highlighting Canadian innovation and the ongoing research behind Biosenta's proprietary Tri-FillerTM technology.
Biotechnology, Chemical, Household / Consumer / Cosmetics
2026-08-14 9:06 AM EDT | Biosenta Inc.
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival benefit observed between 2-year and 2.5-year timepoints U.K. MHRA Statistical Methods Scientific Advice Meeting gra
2026-08-13 8:45 AM EDT | OS Therapies
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnology, Pharmaceuticals, Health
2026-08-12 8:23 AM EDT | Hemostemix Inc.
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines. PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D P
Biotechnology, Pharmaceuticals
2026-08-11 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) -
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:30 AM EDT | BioHarvest Sciences Inc.
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has officially commenced commercial production of its highly anticipated new protein-focused product line. This marks a significant milestone in the Company's product development roadmap and underscores its core focus on revenue gener
Technology, Biotechnology, Health
2026-08-11 6:00 AM EDT | Restart Life Sciences Corp.
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences I
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:00 AM EDT | BioHarvest Sciences Inc.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Theralase(R) Announces $5 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Age
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-10 5:15 PM EDT | Theralase Technologies Inc.
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today re
Biotechnology, Healthcare and Hospitals
2026-08-10 8:00 AM EDT | Envoy Medical, Inc.
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible par
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-07 5:25 PM EDT | Theralase Technologies Inc.
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities. Second Quarter 2026 and Recent Highlights Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort
Biotechnology, Pharmaceuticals
2026-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.